Grant Chappell, Amir Mehdizadeh-Shrifi, Darren Turner, Alexander Bondoc, Suzanne Evans, Alexander G Miethke, Gregory Tiao, Meghan M Chlebowski, Alexander R Opotowsky, David Lehenbauer, Marco Ricci, Awais Ashfaq, David L S Morales
Background: With increasing numbers of patients surviving Fontan palliation, there is a rise in Fontan-associated liver disease and transplantation strategies inclusive of combined heart-liver transplantation (CHLT). Therefore, we reviewed a combined dataset assessing outcomes of pediatric patients undergoing CHLT.
Methods: Patients undergoing Fontan CHLT between 2010 and 2024 at pediatric hospitals were queried from a merged dataset of the Pediatric Health Information System and United Network for Organ Sharing. Matching (2:1) was completed with Fontan heart-only transplant recipients.
Results: A total of 34 patients underwent Fontan CHLT at 9 pediatric hospitals between 2010 and 2024, 82% (n = 28) after 2019. Almost one-half (47%; n = 16) were age ≤18 years at the time of CHLT, with a median age of 19 years (interquartile range, 15-24 years). More than two-thirds (68%) had hypoplastic left heart syndrome, 38% had double-inlet left ventricle, 26% had double-outlet right ventricle, and 18% had tricuspid atresia. One-third of the patients (n = 11) had a Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease score of ≤10 at CHLT, with 91% hospital survival, and those with a score >10 had 82% survival. One-year survival was 85% overall, 94% for those age >18 years, and 75% for those age ≤18 years. All deaths occurred before hospital discharge and within 6 months of transplantation, with a mean follow-up of 4 years. Three-year survival was similar in the CHLT and heart transplant -only (HT) groups (85% vs 84%; P = .96, log-rank test).
Conclusions: This multi-institutional analysis demonstrates the rapidly increasing numbers of Fontan palliated patients successfully undergoing CHLT in pediatric hospitals. Conditional on surviving to discharge, long-term survival has been excellent, demonstrating a success story in transplantation management for this complex population.
Intended audience: Healthcare professionals and clinicians.
What happens when kids who underwent Fontan procedure don't just need a new heart, but a new liver as well. I'm Lizzie Lee from Cincinnati Children's, and this is an article you should know about. As more Fontan patients are surviving in adolescence and adulthood, liver disease is becoming a rising issue, and combined heart liver transplantation is happening more often. This study looked at children and young adults undergoing combined heart liver transplant at hospitals across the US in the last few years. Many of the patients were complex and had hypoplastic left heart syndrome. Despite that, survival was strong after combined heart liver transplant. About 85% survived at 1 year, and long-term outcomes were excellent. Even more striking, 3-year survival was basically identical to patients who received a heart transplant alone. The big takeaway, combined heart liver transplant is effective and increasingly common for Fontan patients with advanced liver disease. Let us know what you think in the comments below and stay tuned for more articles that you should know about.
Click "Show Transcript" to view the full transcription (1086 characters)
Comments